The blog post discusses the expansion of an agreement between Exobiosphere and Voyager Technologies for commercial biotech research in microgravity. It highlights two new research campaigns that will be conducted aboard the International Space Station (ISS), specifically utilizing Exobiosphere’s automated drug screening system, the Orbital High-Throughput Screening in Microgravity (OHTS) platform.